Published Date: 22 Apr 2023
The National Cancer Plan was created by Dr. Monica Bertagnolli at the National Cancer Institute to assist President Joe Biden's Cancer Moonshot initiative.
Read Full NewsA phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.
In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.
A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.
Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma
Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention
6 Ophthalmology Headlines You Missed in October 2025
1.
Tumor-targeting fluorescent bacteria illuminate cancer for precision surgery
2.
Researchers discover cellular 'doorway' exploited by cancer-causing virus
3.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
4.
Short-course radiation matches standard therapy for endometrial cancer
5.
Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue
1.
Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership
2.
AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology
3.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
4.
The Risk Factors of Venous Thromboembolism and How to Lower Your Chances
5.
Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation